BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, Bindslev L, Haack-Sørensen M, Jørgensen E, Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J. 2008;42:295-302. [PMID: 18615353 DOI: 10.1080/14017430802220567] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Esteghamati A, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. J Endocrinol Invest 2014;37:1211-8. [PMID: 25138574 DOI: 10.1007/s40618-014-0154-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
2 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
3 Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. [PMID: 19930630 DOI: 10.1186/1475-2840-8-61] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 8.8] [Reference Citation Analysis]
4 Pawlak K, Rozkiewicz D, Mysliwiec M, Pawlak D. YKL-40 in hemodialyzed patients with and without cardiovascular complications – The enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine 2013;62:75-80. [DOI: 10.1016/j.cyto.2013.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sørensen K, Klingvall MF, Brosstad F, Oie E, Vestergaard H, Aukrust P, Halvorsen B. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 2010;211:589-95. [PMID: 20347092 DOI: 10.1016/j.atherosclerosis.2010.02.035] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
6 Thomsen SB, Gjesing AP, Rathcke CN, Ekstrøm CT, Eiberg H, Hansen T, Pedersen O, Vestergaard H. Associations of the Inflammatory Marker YKL-40 with Measures of Obesity and Dyslipidaemia in Individuals at High Risk of Type 2 Diabetes. PLoS One 2015;10:e0133672. [PMID: 26197239 DOI: 10.1371/journal.pone.0133672] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
7 Schaller G, Brix JM, Placher-sorko G, Höllerl F, Schernthaner G, Schernthaner G. YKL-40 concentrations are not elevated in gestational diabetes. European Journal of Clinical Investigation 2010;40:339-43. [DOI: 10.1111/j.1365-2362.2010.02274.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
8 Akboga MK, Yalcin R, Sahinarslan A, Yilmaz Demirtas C, Abaci A. Effect of serum YKL-40 on coronary collateral development and SYNTAX score in stable coronary artery disease. International Journal of Cardiology 2016;224:323-7. [DOI: 10.1016/j.ijcard.2016.09.042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
9 Rathcke CN, Kjøller E, Fogh-Andersen N, Zerahn B, Vestergaard H. NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease. PLoS One 2010;5:e14196. [PMID: 21152016 DOI: 10.1371/journal.pone.0014196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
10 Di Rosa M, Brundo VM, Malaguarnera L. New insights on chitinases immunologic activities. World J Immunol 2016; 6(2): 96-104 [DOI: 10.5411/wji.v6.i2.96] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Henningsen KM, Nilsson B, Johansen JS, Chen X, Pehrson S, Svendsen JH. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res 2010;59:463-9. [PMID: 20012147 DOI: 10.1007/s00011-009-0146-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
12 Jönsson M, Gerdle B, Ghafouri B, Bäckryd E. The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study. BMC Neurosci 2021;22:6. [PMID: 33522900 DOI: 10.1186/s12868-021-00608-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kim MN, Lee KE, Hong JY, Heo WI, Kim KW, Kim KE, Sohn MH. Involvement of the MAPK and PI3K pathways in chitinase 3-like 1-regulated hyperoxia-induced airway epithelial cell death. Biochem Biophys Res Commun 2012;421:790-6. [PMID: 22554524 DOI: 10.1016/j.bbrc.2012.04.085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
14 Batinic K, Höbaus C, Grujicic M, Steffan A, Jelic F, Lorant D, Hörtenhuber T, Hoellerl F, Brix JM, Schernthaner G, Koppensteiner R, Schernthaner GH. YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes. Atherosclerosis 2012;222:557-63. [PMID: 22572101 DOI: 10.1016/j.atherosclerosis.2012.03.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
15 Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. [PMID: 24634660 DOI: 10.3389/fphys.2014.00075] [Cited by in Crossref: 244] [Cited by in F6Publishing: 263] [Article Influence: 30.5] [Reference Citation Analysis]
16 Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers 2017;22:261-7. [PMID: 27325138 DOI: 10.1080/1354750X.2016.1204003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Tsantilas P, Lao S, Wu Z, Eberhard A, Winski G, Vaerst M, Nanda V, Wang Y, Kojima Y, Ye J, Flores A, Jarr KU, Pelisek J, Eckstein HH, Matic L, Hedin U, Tsao PS, Paloschi V, Maegdefessel L, Leeper NJ. Chitinase 3 like 1 (CHI3L1) is a regulator of smooth muscle cell physiology and atherosclerotic lesion stability. Cardiovasc Res 2021:cvab014. [PMID: 33471078 DOI: 10.1093/cvr/cvab014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Keles ZP, Keles GC, Avci B, Cetinkaya BO, Emingil G. Analysis of YKL-40 Acute-Phase Protein and Interleukin-6 Levels in Periodontal Disease. Journal of Periodontology 2014;85:1240-6. [DOI: 10.1902/jop.2014.130631] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
19 Gonen T, Guzel S, Keskinbora KH. YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome. Eye (Lond) 2019;33:772-6. [PMID: 30560917 DOI: 10.1038/s41433-018-0308-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lappegård KT, Hovland A, Pop GA, Mollnes TE. Atrial fibrillation: inflammation in disguise? Scand J Immunol 2013;78:112-9. [PMID: 23672430 DOI: 10.1111/sji.12061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
21 Yasuda T, Kaneto H, Katakami N, Kuroda A, Matsuoka TA, Yamasaki Y, Matsuhisa M, Shimomura I. YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract 2011;91:e50-2. [PMID: 21159401 DOI: 10.1016/j.diabres.2010.11.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
22 Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology 2013;218:945-51. [PMID: 23294528 DOI: 10.1016/j.imbio.2012.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
23 Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, Gøtze JP, Johansen JS, Kastrup J. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scandinavian Journal of Clinical and Laboratory Investigation 2011;71:439-47. [DOI: 10.3109/00365513.2011.586470] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
24 Adamidi T, Soulitzis N, Neofytou E, Zannetos S, Georgiou A, Benidis K, Papadopoulos A, Siafakas NM, Schiza SE. Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study. BMC Pulm Med 2015;15:150. [PMID: 26620310 DOI: 10.1186/s12890-015-0144-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 El-asrar MA, Elbarbary NS, Ismail EAR, Elshenity AM. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications. Blood Cells, Molecules, and Diseases 2016;56:1-8. [DOI: 10.1016/j.bcmd.2015.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Thomsen SB, Rathcke CN, Skaaby T, Linneberg A, Vestergaard H. The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population. PLoS One 2012;7:e47094. [PMID: 23071724 DOI: 10.1371/journal.pone.0047094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
27 Xu Y, Meng HL, Su YM, Chen C, Huang YH, Li XF, Fan MK, Yan YJ, Wu J, Jiang MH, Pan M. Serum YKL-40 is increased in patients with slow coronary flow. Coron Artery Dis 2015;26:121-5. [PMID: 25356814 DOI: 10.1097/MCA.0000000000000191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Lee CG, Elias JA. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. Allergy Asthma Immunol Res 2010;2:20-7. [PMID: 20224674 DOI: 10.4168/aair.2010.2.1.20] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
29 Lin CH, Li HY, Jiang YD, Chang TJ, Chuang LM. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes. Clin Endocrinol (Oxf) 2013;79:185-91. [PMID: 22901243 DOI: 10.1111/cen.12015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
30 Brix J, Höllerl F, Koppensteiner R, Schernthaner G, Schernthaner G. YKL-40 in type 2 diabetic patients with different levels of albuminuria: YKL-40 IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT LEVELS OF ALBUMINURIA. European Journal of Clinical Investigation 2011;41:589-96. [DOI: 10.1111/j.1365-2362.2010.02446.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
31 Huang CJ, Slusher AL, Whitehurst M, Wells M, Maharaj A, Shibata Y. The impact of acute aerobic exercise on chitinase 3-like protein 1 and intelectin-1 expression in obesity. Exp Biol Med (Maywood) 2016;241:216-21. [PMID: 26316585 DOI: 10.1177/1535370215602785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Erfan G, Guzel S, Alpsoy S, Rifaioglu EN, Kaya S, Kucukyalcın V, Topcu B, Kulac M. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Mol Cell Biochem 2015;400:207-12. [PMID: 25421412 DOI: 10.1007/s11010-014-2277-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
33 Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010;68:672-80. [DOI: 10.1002/ana.22220] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
34 Deng Y, Li G, Chang D, Su X. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clin Chim Acta 2020;511:40-6. [PMID: 33002471 DOI: 10.1016/j.cca.2020.09.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Rathcke CN, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Lip GY, Faber J, Vestergaard H. Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand Cardiovasc J 2010;44:92-9. [PMID: 19961288 DOI: 10.3109/14017430903402218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
36 Chavan V, Sabavath S, Babu CH, Boyapati L. Estimation of YKL-40 Acute-Phase Protein in Serum of Patients with Periodontal Disease and Healthy Individuals: A Clinical-Biochemical Study. Contemp Clin Dent 2019;10:249-55. [PMID: 32308286 DOI: 10.4103/ccd.ccd_471_18] [Reference Citation Analysis]
37 Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjoller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; the CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal 2009;30:1066-72. [DOI: 10.1093/eurheartj/ehp049] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 9.2] [Reference Citation Analysis]
38 Sakazaki Y, Hoshino T, Takei S, Sawada M, Oda H, Takenaka S, Imaoka H, Matsunaga K, Ota T, Abe Y, Miki I, Fujimoto K, Kawayama T, Kato S, Aizawa H. Overexpression of chitinase 3-like 1/YKL-40 in lung-specific IL-18-transgenic mice, smokers and COPD. PLoS One 2011;6:e24177. [PMID: 21915293 DOI: 10.1371/journal.pone.0024177] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
39 Türkyılmaz K, Öner V, Kırbas A, Sevim MS, Sekeryapan B, Özgür G, Durmus M. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye (Lond) 2013;27:854-9. [PMID: 23661157 DOI: 10.1038/eye.2013.92] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
40 Malyszko J, Koc-zorawska E, Malyszko J. YKL-40, a Marker of Cardiovascular Disease and Endothelial Dysfunction, in Kidney Transplant Recipients. Transplantation Proceedings 2014;46:2651-3. [DOI: 10.1016/j.transproceed.2014.09.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
41 Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med 2014;8:977-87. [PMID: 25343670 DOI: 10.2217/bmm.14.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 2012;217:652-6. [PMID: 22209156 DOI: 10.1016/j.imbio.2011.11.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
43 Krečak I, Gverić-Krečak V, Lapić I, Rončević P, Gulin J, Fumić K, Krečak F, Holik H, Duraković N. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms. Acta Clin Belg 2021;76:32-9. [PMID: 31455178 DOI: 10.1080/17843286.2019.1659467] [Reference Citation Analysis]
44 Wu Y, Tao Z, Song C, Jia Q, Bai J, Zhi K, Qu L. Overexpression of YKL-40 predicts plaque instability in carotid atherosclerosis with CagA-positive Helicobacter pylori infection. PLoS One 2013;8:e59996. [PMID: 23573226 DOI: 10.1371/journal.pone.0059996] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
45 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
46 Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gøtze JP, Johansen JS, Kastrup J; The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011;60:281-7. [DOI: 10.1007/s00011-010-0266-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
47 Lee H, Kang R, Jee SH, Yoon Y. A promoter polymorphism −2122C>T of CHI3L1 is associated with serum low density lipoprotein cholesterol level in Korean subjects. Clinical Biochemistry 2010;43:1195-200. [DOI: 10.1016/j.clinbiochem.2010.07.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
48 Jiang L, Wang Y, Peng Q, Shu X, Wang G, Wu X. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol 2019;38:1655-63. [DOI: 10.1007/s10067-019-04457-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
49 Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol. 2010;9:86. [PMID: 21143859 DOI: 10.1186/1475-2840-9-86] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
50 Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 2009;11:1032-6. [PMID: 19411674 DOI: 10.1093/europace/eup103] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
51 Rathcke CN, Thomsen SB, Linneberg A, Vestergaard H. Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS One 2012;7:e43498. [PMID: 22937056 DOI: 10.1371/journal.pone.0043498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
52 Huang CJ, Beasley KN, Acevedo EO, Franco RL, Jones TL, Mari DC, Shibata Y. Chitin enhances obese inflammation ex vivo. Hum Immunol 2014;75:41-6. [PMID: 24055693 DOI: 10.1016/j.humimm.2013.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Marott SC, Benn M, Johansen JS, Jensen GB, Tybjærg-Hansen A, Nordestgaard BG. YKL-40 levels and atrial fibrillation in the general population. Int J Cardiol 2013;167:1354-9. [PMID: 22525348 DOI: 10.1016/j.ijcard.2012.04.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
54 Musumeci M, Caruso V, Medulla E, Torrisi V, Migale R, Angeletti S, Musumeci S. Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major. Dis Markers 2014;2014:965971. [PMID: 24808626 DOI: 10.1155/2014/965971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Foroughi M, Mohammadi Z, Majidi Tehrani M, Bakhtiari M, Dabbagh A, Haji Molahoseini M. The Effect of Erythropoietin Administration on the Serum Level of YKL-40, pro-BNP and IL-6 in Coronary Surgery Patients. Iran J Pharm Res 2020;19:430-9. [PMID: 33680042 DOI: 10.22037/ijpr.2020.112867.13993] [Reference Citation Analysis]
56 Di Rosa M, Distefano G, Zorena K, Malaguarnera L. Chitinases and immunity: Ancestral molecules with new functions. Immunobiology 2016;221:399-411. [PMID: 26686909 DOI: 10.1016/j.imbio.2015.11.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
57 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
58 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
59 Schroder J, Jakobsen JC, Winkel P, Hilden J, Jensen GB, Sajadieh A, Larsson A, Ärnlöv J, Harutyunyan M, Johansen JS, Kjøller E, Gluud C, Kastrup J. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease. J Am Heart Assoc 2020;9:e014634. [PMID: 32114892 DOI: 10.1161/JAHA.119.014634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
60 Tan Y, Ji X, Mo Z, Zhou Y. Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment. Medicine (Baltimore) 2019;98:e17950. [PMID: 31764795 DOI: 10.1097/MD.0000000000017950] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Michelakakis N, Neroutsos GJ, Perpinia AS, Farmakis D, Voukouti EG, Karavidas AJ, Parissis J, Georgiakaki MT, Pyrgakis VN. Chitinase-3-like protein-1 (YKL-40) before and after therapy in supraventricular arrhythmias: . Journal of Cardiovascular Medicine 2017;18:650-4. [DOI: 10.2459/jcm.0000000000000539] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
62 Wu S, Hsu LA, Cheng ST, Teng MS, Yeh CH, Sun YC, Huang HL, Ko YL. Circulating YKL-40 level, but not CHI3L1 gene variants, is associated with atherosclerosis-related quantitative traits and the risk of peripheral artery disease. Int J Mol Sci 2014;15:22421-37. [PMID: 25486056 DOI: 10.3390/ijms151222421] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
63 Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013;273:205-16. [PMID: 23140269 DOI: 10.1111/joim.12006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
64 Matsuura H, Hartl D, Kang MJ, Dela Cruz CS, Koller B, Chupp GL, Homer RJ, Zhou Y, Cho WK, Elias JA, Lee CG. Role of breast regression protein-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema. Am J Respir Cell Mol Biol 2011;44:777-86. [PMID: 20656949 DOI: 10.1165/rcmb.2010-0081OC] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
65 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
66 Komi DE, Kazemi T, Bussink AP. New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma. Curr Allergy Asthma Rep 2016;16:57. [PMID: 27438466 DOI: 10.1007/s11882-016-0637-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
67 Pala S, Sari M, Kahveci G, Alizade E, Arslantas U, Uslu A. Plasma YKL-40 Elevation on Admission and Follow-Up Is Associated with Diastolic Dysfunction and Mortality in Patients with Acute Myocardial Infarction. Cardiol Res Pract 2018;2018:8701851. [PMID: 29686891 DOI: 10.1155/2018/8701851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
68 Rani R, Singh V. Overexpression of YKL-40 (CHI3L1 gene) in patient fluids may be a potential predictive marker for early detection of comorbidity in non-communicable disease. Med Hypotheses 2020;143:110076. [PMID: 32721792 DOI: 10.1016/j.mehy.2020.110076] [Reference Citation Analysis]
69 Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit Rev Clin Lab Sci 2016;53:396-408. [PMID: 27187575 DOI: 10.1080/10408363.2016.1190683] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
70 Turkyilmaz AK, Devrimsel G, Kirbas A, Cicek Y, Karkucak M, Capkin E, Gokmen F. Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis. Rheumatol Int 2013;33:2751-6. [DOI: 10.1007/s00296-013-2810-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
71 Hedegaard A, Ripa RS, Johansen JS, Jørgensen E, Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010;70:80-6. [PMID: 20102300 DOI: 10.3109/00365510903518191] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
72 Mygind ND, Axelsson A, Ruwald MH, Dalsgaard M, Steffensen R, Iversen K, Johansen JS, Kastrup J. The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. Cardiovasc Endocrinol 2016;5:21-7. [PMID: 28392973 DOI: 10.1097/XCE.0000000000000073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]